You are here: Industry Insights > Trulicity

News List

FDA Approves Additional Doses of Trulicity (dulaglutide) for the Treatment of Type 2 Diabetes drugs.com
September 23, 2020
The U.S. Food and Drug Administration (FDA) today approved two additional doses of Eli Lilly and Company's (NYSE: LLY) Trulicity® (dulaglutide). The approval expands the label of once-weekly Trulicity to include 3.0 mg and 4.5 mg doses based on data from
FDA Approves Additional Doses of Trulicity for Type 2 Diabetes americanpharmaceuticalreview
September 07, 2020
The U.S. Food and Drug Administration (FDA) has approved two additional doses of Eli Lilly and Company's Trulicity® (dulaglutide).
Lilly gets US FDA nod for additional doses of Trulicity (dulaglutide) to treat type 2 diabetes expresspharma
September 07, 2020
The US Food and Drug Administration (FDA) approved two additional doses of Eli Lilly and Company’s Trulicity (dulaglutide). The approval expands the label of once-weekly Trulicity to include 3.0 mg and 4.5 mg doses based on data from AWARD-11.
Lilly says diabetes drug Trulicity reduces heart risks in trial expressbpd
November 08, 2018
The company did not provide any details on the magnitude of risk reduction seen in the so-called outcomes trial
Lilly’s Trulicity shows superiority in reducing CV events in type 2 diabetes pharmaceutical-technology
November 07, 2018
Global pharmaceutical company Eli Lilly has announced its Trulicity (dulaglutide) has demonstrated superiority to placebo combined with standard of care in reducing the number of major adverse cardiovascular (CV) events (MACE) in patients with type 2 diab